SCIENTIFIC POSTER_Sezin Ozdogan Erkul_1

In this study we wanted to compare efficacy and safety of bevacizumab and ranibizumab in treatment of macular edema due to branch retinal vein occlusion depending on the duration of macular edema. An institutional review board approved retrospective survey was done among 58 eyes of 57 patients having macular edema due to branch retinal vein occlusion. Patients were grouped according to the initial treatment modality. Patients receiving either intravitreal Bevacizumab (1.25mg/0,05ml) or Ranibizumab (0.5mg/0,05ml) as a first line therapy, at a single center during the period of last 2 years, were included in the study. Patients were also subgrouped according to duration of visual disturbances : Early treatment (less than 3 months of onset) and Late treatment (more than 3 months of onset). Macula was evaluated both clinically and with Optovue Optical Coherence Tomography (OCT) and central macular thickness (CMT) greater than 250 microns were defined as macular edema. Treatment was based on an « as needed » protocol according to best corrected visual acuity (BCVA), ophthalmologic examination and OCT findings. 58 eyes of 57 patients having macular edema due to branch retinal vein occlusion were included in the study. Intravitreal Bevacizumab was used in 33 (56,9%) eyes and Ranibizumab was used in 25 (43,1%) eyes. Baseline CMT was 563,5 ± 112 (351-786) in bevacizumab group and 493.8 ± 114 (276-704) in ranibizumab group. Baseline best corrected visual acuity in LogMAR was 1.07 ± 0,5 in bevacizumab group and 0,95 ± 0,5 in ranibizumab group. There was 31,3% early treatment in in bevacizumab group and 47.4% early treatment in ranibizumab group. There was no statistically significant difference between demographic characteristics, BCVA and CMTs of two groups and subgroups. (p>0,05) At the end of this retrospective survey, it was seen that there are no significant differences in means of BCVA and CMT between Bevacizumab and Ranibizumab in early treatment as well as there are no significant differences in means of BCVA and CMT between Bevacizumab and Ranibizumab in late treatment. Either Bevacizumab or Ranibizumab can be used safely and effectively in treatment of macular edema due to branch retinal vein occlusion in both early and late phases of the disease as a first line trerapy.